KVYO (KVYO) shareholder outlines 757 Series A share sale on NYSE in SEC notice

Rhea-AI Filing Summary

A shareholder has filed a notice to sell 757 Series A shares. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 22822.56 and 137856147 Series A shares reported as outstanding.

The 757 shares were originally acquired on 09/25/2012 as founders shares from the issuer, paid as compensation. The notice also lists prior three‑month sales by Hodgkins Trust and Hodgkins LLC, including 22224 and 67524 Series A shares sold on 09/15/2025 for gross proceeds of 703493.05 and 2142377.45. The seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Series A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	757	22822.56	137856147	12/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Series A	09/25/2012	Founders Shares	Issuer			757	09/25/2012	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hodgkins Trust 125 Summer Street 6th Floor Boston MA 02110	Series A	09/15/2025	22224	703493.05
Hodgkins Llc 125 Summer Street 6th Floor Boston MA 02110	Series A	09/15/2025	67524	2142377.45
Hodgkins Trust 125 Summer Street 6th Floor Boston MA 02110	Series A	11/10/2025	8572	257604.18
Hodgkins Llc 125 Summer Street 6th Floor Boston MA 02110	Series A	11/10/2025	50920	1529816.71
Hodgkins Trust 125 Summer Street 6th Floor Boston MA 02110	Series A	11/11/2025	545	16350.54
Hodgkins Llc 125 Summer Street 6th Floor Boston MA 02110	Series A	11/11/2025	2266	67981.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What KVYO share sale is disclosed in this notice?

The notice states that a shareholder plans to sell 757 Series A shares of the issuer. These shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 22822.56.

How many KVYO Series A shares are reported as outstanding?

The filing reports that there are 137856147 Series A shares outstanding. This figure provides a baseline for understanding the size of the planned 757‑share sale.

When and how were the KVYO shares to be sold originally acquired?

The 757 Series A shares to be sold were acquired on 09/25/2012 as founders shares from the issuer. The nature of payment is listed as compensation, indicating they were received as part of a compensation arrangement rather than a cash purchase.

What prior KVYO share sales over the last 3 months are disclosed?

The notice lists several Series A sales by Hodgkins Trust and Hodgkins LLC. Examples include 22224 shares sold on 09/15/2025 for gross proceeds of 703493.05 and 67524 shares sold the same day for 2142377.45, along with additional sales on 11/10/2025 and 11/11/2025.

What representation does the seller make about KVYO in this notice?

By signing, the person for whose account the securities are to be sold represents that they do not know any material adverse information regarding the issuer’s current and prospective operations that has not been publicly disclosed.

Does the KVYO notice reference Rule 10b5-1 trading plans?

The form language explains that if the person relies on a written trading plan or trading instructions under Rule 10b5-1, then by signing and providing the plan adoption or instruction date, they make the same representation as of that adoption or instruction date.